中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

593 records (took 0.048 seconds)

    TREATMENT PARADIGM
    64.
    发明申请
    TREATMENT PARADIGM 审中-公开

    公开(公告)号：US20190322734A1

    公开(公告)日：2019-10-24

    申请号：US15772664

    申请日：2016-10-31

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Paul-Peter TAK

    IPC: C07K16/24 ,  A61K39/395 ,  A61K31/519

    Abstract: An antibody antagonist of GM-CSF for use in the treatment of a patient suffering from rheumatoid arthritis (RA), wherein said antibody is administered to said patient according to the following treatment regimen: i. a first period wherein the antibody is administered once a week; and ii. a second period wherein the antibody is administered every other week and then ceased once said patient has sustained remission for a continuous period of at least two months.

    NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
    67.
    发明申请
    NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS 审中-公开

    公开(公告)号：US20190247382A1

    公开(公告)日：2019-08-15

    申请号：US16376858

    申请日：2019-04-05

    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

    Inventor： Michael P. Demartino ,  Huiping Amy Guan

    IPC: A61K31/4439 ,  A61K31/4412 ,  C07D213/69

    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

    ICOS binding proteins
    70.
    发明授权
    ICOS binding proteins 有权

    公开(公告)号：US10351627B2

    公开(公告)日：2019-07-16

    申请号：US15246662

    申请日：2016-08-25

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Yao-Bin Liu ,  Patrick Mayes ,  Radha Shah Parmar

    IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30 ,  A61K39/00

    Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

Patent Agency Ranking